Is Verastem, Inc. (VSTM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.8% / 30% | 18.5% / 30% | 0.0% / 30% | 41.49% / 5% | ✗ NOT HALAL |
| DJIM | 8.8% / 33% | 18.5% / 33% | 0.0% / 33% | 41.49% / 5% | ✗ NOT HALAL |
| MSCI | 41.6% / 33% | 87.5% / 33% | 0.2% / 33% | 41.49% / 5% | ✗ NOT HALAL |
| S&P | 8.8% / 33% | 18.5% / 33% | 0.0% / 33% | 41.49% / 5% | ✗ NOT HALAL |
| FTSE | 41.6% / 33% | 87.5% / 33% | 0.2% / 50% | 41.49% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 85.1% | |
| Operating Margin | -236.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1480.2% | |
| Return on Assets (ROA) | -61.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$138M |
| Free Cash Flow | -$147M |
| Total Debt | $87M |
| Debt-to-Equity | 152.4 |
| Current Ratio | 3.1 |
| Total Assets | $246M |
Price & Trading
| Last Close | $5.29 |
| 50-Day MA | $6.01 |
| 200-Day MA | $7.39 |
| Avg Volume | 1.8M |
| Beta | 0.4 |
|
52-Week Range
$4.01
| |
About Verastem, Inc. (VSTM)
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Verastem, Inc. (VSTM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Verastem, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Verastem, Inc.'s debt ratio?
Verastem, Inc.'s debt ratio is 8.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 41.6%.
What are Verastem, Inc.'s key financial metrics?
Verastem, Inc. has a market capitalization of $443M, and revenue of $31M. Return on equity stands at -1480.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.